Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pulmonary arterial hypertension
Pharma
FDA balks at standard nod to Liquidia's PAH rival to United med
The agency granted a broad regulatory exclusivity to rival United Therapeutics and its Tyvasvo DPI, leaving Liquidia's Yutrepia in FDA limbo until 2025.
Zoey Becker
Aug 19, 2024 11:34am
Aerovate's stock plummets after sole product fails in PAH trial
Jun 17, 2024 7:25pm
Sponsored
Merck joins ALA's pulmonary arterial hypertension awareness push
Nov 14, 2024 10:50am
Merck aims to 'outnumber' pulmonary arterial hypertension
Apr 16, 2024 10:37am
Courts clear FDA to approve Liquidia's PAH drug Yutrepia
Apr 2, 2024 9:33am
FDA signs off on Merck’s potential blockbuster Winrevair for PAH
Mar 26, 2024 5:11pm
